Related Experiment Videos
Angiotensin converting enzyme in bleomycin-treated patients
N Nussinovitch1, E Peleg, A Yaron
1Department of Medicine D, Chaim Sheba Medical Center, Tel Hashomer, Israel.
International Journal of Clinical Pharmacology, Therapy, and Toxicology
|June 1, 1988
Summary
Bleomycin chemotherapy affects angiotensin converting enzyme (ACE) activity differently based on dosage. High-dose bleomycin in testicular cancer patients showed a prolonged ACE elevation, suggesting potential prognostic value.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Bleomycin is a chemotherapy agent used for various cancers.
- Angiotensin converting enzyme (ACE) plays a role in blood pressure regulation and inflammation.
- The impact of bleomycin on ACE activity requires further investigation.
Purpose of the Study:
- To investigate the effect of different bleomycin dosages on serum angiotensin converting enzyme (ACE) activity.
- To determine if ACE activity monitoring can aid in prognosis for patients receiving bleomycin.
Main Methods:
- Serum ACE activity was measured in two groups of patients undergoing bleomycin combination therapy.
- Group 1: Squamous cell carcinoma patients received low-dose bleomycin (Price et al. protocol).
- Group 2: Testicular tumor patients received high-dose bleomycin (Einhorn and Donohue protocol).
Main Results:
- No significant change in serum ACE activity was observed in the low-dose bleomycin group.
- A delayed and sustained increase in serum ACE activity was noted in the high-dose bleomycin group.
- This elevation was independent of acute bleomycin administration.
Conclusions:
- High-dose bleomycin therapy is associated with a prolonged elevation of serum ACE activity.
- Monitoring ACE activity may offer prognostic insights for patients treated with high-dose bleomycin.
- Further research is warranted to elucidate the clinical utility of ACE monitoring in bleomycin therapy.